Kat Attica General Hospital
- Address
- lock Available on a paid plan
KAT Attika General Hospital - Emergency and Cardiovascular Research Center
KAT Attika General Hospital serves as a prominent clinical research facility specializing in emergency medicine, cardiovascular interventions, and acute care therapeutics. The center demonstrates particular expertise in conducting comparative effectiveness trials and emergency department-based cardiovascular studies, with a strong focus on patient-centered outcomes and innovative treatment approaches.
- Emergency cardiovascular management, including pharmacological cardioversion of atrial fibrillation in patients with coronary disease
- Acute coronary syndrome and secondary prevention strategies following myocardial infarction
- Acute pain management and low back pain therapeutics, comparing combination therapies and novel analgesic approaches
- Sepsis endotype-driven treatment strategies targeting interferon-gamma pathways
The hospital's research portfolio reflects a comprehensive approach to emergency and critical care medicine, investigating conditions ranging from acute coronary syndrome to IFNγ-driven sepsis. Through participation in both large international multicenter trials and focused comparative effectiveness studies, KAT Attika contributes valuable data on cardiovascular pharmacotherapy, advanced sepsis management with immunomodulatory agents, and evidence-based approaches to acute musculoskeletal pain. The center's involvement in studies evaluating novel anticoagulants, anti-inflammatory combinations, and precision medicine approaches in sepsis demonstrates its commitment to advancing therapeutic options for patients with acute and life-threatening conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Verisfield Single Member S.A.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Verisfield Single Member S.A.3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kat Attica General Hospital
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Randomized Trial Comparing Flecainide Acetate and Amiodarone Hydrochloride for Cardioversion of Paroxysmal Atrial Fibrillation in Coronary Artery Disease | Win Medica Pharmaceutical S.A. | Phase III | Not Recruiting | Apr 2023 | Jan 2026 |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| DICLOFENAC POTASSIUM | 2 | Unknown | 2026-04-05 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.